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Introduction {#sec001}
============

Preoperative concurrent chemoradiotherapy (CCRT), as an important part of the comprehensive treatment of locally advanced rectal cancer (LARC), has been widely applied in clinical practice with an effective rate of approximately 40--80% \[[@pone.0234310.ref001]--[@pone.0234310.ref004]\]. However, there are many patients who cannot benefit from this type of treatment. In addition, preoperative CCRT may result in pelvic connective tissue fibrosis, radiation enteritis, along with other side effects that can lead to postoperative complications such as anastomotic leakage, and defects in wound healing. Therefore, it is of great significance to explore a method of selecting patients with no/low response to CCRT before treatment.

Cancer stem cells (CSCs) have a strong self-renewal ability, DNA repair ability, hypoxic survival ability, and high radiation resistance \[[@pone.0234310.ref005]--[@pone.0234310.ref009]\]. It was found that CD44 positive tumor cells have a series of stem cell characteristics, such as strong proliferation, invasion, anti-apoptosis, and stable passage \[[@pone.0234310.ref010]--[@pone.0234310.ref014]\]. Therefore, the researchers believe that CD44 can be used as an important marker of CSCs \[[@pone.0234310.ref015], [@pone.0234310.ref016]\].

Currently, accumulating clinical evidence is emerging, indicating that CD44 and its variant isoforms can predict a patient's resistance to radiation. Xiao et al. \[[@pone.0234310.ref017]\] found that the up-regulated expression of CD44 contributes to the cell cycle arrest of prostate cancer cells and the repair of DNA double-strand breaks (DSB), consequently enhancing the radiation resistance. Huh et al. screened the expression of 13 factors that may affect the efficacy of preoperative CCRT in 123 LARC patients and found that the up-regulation of CD44 expression in tumor tissues before treatment predicted poor tumor regression \[[@pone.0234310.ref018]\]. Sagawa K et al. \[[@pone.0234310.ref015]\] found that patients with nasopharyngeal carcinoma and high expression of CD44v6 had poor clinical response to CCRT, and analysis of its expression would be helpful in predicting the prognosis of patients.

In view of this, the study also included the expression of CD44v6 in primary tumor tissue. At the same time, the general clinical data (age, gender, clinical T stage, clinical N stage, carcinoembryonic antigen (CEA) and pathological type) and imaging volume parameters (tumor maximum longitudinal length (TML), tumor maximum transverse diameter (TMD), approximate tumor volume (ATV), real tumor volume (RTV), tumor surface area inner the intestine (TSAI), tumor surface area outside the intestine (TSAO), total surface area of tumor (TSA), and tumor compactness(TC)) of the primary tumor were included in the study. In order to find a method of predicting the resistance of patients with LARC to CCRT, we used the above 15 factors to analyze the influence of no/low response of 79 patients with LARC after receiving long-course preoperative CCRT at our institute.

Materials and methods {#sec002}
=====================

Patients {#sec003}
--------

The ethics committee of the Fourth Hospital of Hebei Medical University approved this study (2014MEC067). All participants provided written informed consent for inclusion to the study. From May 2015 to August 2017, 79 LARC patients who received long-course preoperative CCRT in our hospital were enrolled. All participants\' information was available to the study group during and after data collection. The eligibility criteria included histologically confirmed adenocarcinoma or mucinous carcinoma, a distance of less than 10cm between the inferior margin of the tumor and the anal verge, clinical T2N+ or clinical T3--4 classification, as well as no distant metastasis confirmed by enhanced abdomen-pelvic MRI and chest CT, availability of contrast-enhanced CT for three-dimensional radiotherapy positioning.

Preoperative CCRT and surgery {#sec004}
-----------------------------

All patients were treated with long-course preoperative CCRT. The total dose of radiotherapy was 50.4Gy and the single dose was 1.8Gy. The target volume delineation and field setup were completed with reference to the ICRU Report 83 and the academic writings of Lee N Y et al. \[[@pone.0234310.ref019]\]. The chemotherapy regimen was to take capecitabine (825mg /m2, bid) orally concurrently with irradiation. Total mesorectal excision (TME) surgery was performed by two surgeons with more than 15 years of experience at 8 to 10 weeks after CCRT, each of whom completed at least 100 rectal cancer surgeries per-year.

The expression of CD44v6 {#sec005}
------------------------

Rectal primary tumor samples obtained pre-treatments by colonoscopy were embedded and sliced into 4-μm-thick sections. The immunohistochemical staining of CD44v6 was performed using the ABC method according to the manufacturer's instructions (Abcam). Breast cancer specimens were used to act as positive control samples, as earlier studies have described that the positive expression rate of CD44v6 in breast cancer tissue was 98.06% \[[@pone.0234310.ref020]\]. PBS substituted primary antibodies were used as negative controls. The results were evaluated by two experienced pathologists who were blind to patient data. The staining scores were performed as follows: no staining or less than 10% positive cells were defined as \"-\", 10--20% weakly to moderately positive cells were \"+\", 10--20% intensively positive cells or 20--50% weakly positive cells were \"+ +\", 20--50% positive cells with moderate to strong reactivity or greater than 50% positive cells were \"+++\" \[[@pone.0234310.ref021]\].

Volumetric imaging parameters {#sec006}
-----------------------------

Pelvic high-resolution MRIs were performed before two weeks of treatment. Referring to these MRI images, we obtained direct and indirect imaging parameters on the radiotherapy localization CT images using Pinnacle version 9.1 system. Direct imaging parameters can be measured and calculated directly from CT images, including the approximate tumor volume (ATV), the tumor maximum longitudinal length (TML) and the tumor maximum transverse diameter (TMD). Indirect image parameters are obtained through the contraction and enlargement function of Pinnacle software, as shown in [Fig 1](#pone.0234310.g001){ref-type="fig"}, including real tumor volume (RTV), tumor surface area inner the intestine(TSAI), tumor surface area outside the intestine (TSAO), total surface area (TSA) and tumor compactness (TC). It should be noted that TC is a secondary derivative parameter, which can be calculated from the following equation \[[@pone.0234310.ref022]--[@pone.0234310.ref024]\], $tumor\ compactness = \frac{real\ tumor\ volume}{{total\ surface\ area}^{1.5}}$.

![Graphical representation of the method for obtaining indirect volumetric image parameters.\
The red line encompasses the approximate tumor volume (ATV). The green line, was generated from ATV with a 3-dimensional universal contraction of 1mm length, and the tumor surface area (TSAO) was the area between the red line and the green line, encompasses the 1mm layer volume. The light green line encompasses the intestinal tube cavity (ITC), the area between the red line and light green line is the real tumor volume (RTV). The blue line was generated from the ITC with a 3-dimensional universal enlargement of 1mm length, and the tumor surface area inner the intestine (TSAI) was the area between the blue line and the light green line, encompasses the 1mm layer volume. Total surface area (TSA) was the sum value of TSAO and TSAI.](pone.0234310.g001){#pone.0234310.g001}

Evaluation of pathologic response to preoperative CCRT {#sec007}
------------------------------------------------------

After 8 weeks of CCRT, we performed a preoperative MRI examination and compared with images before CCRT to evaluate the changes of the primary tumor, local positive lymph nodes and circumferential resection margin (CRM). Since the MRI results cannot fully reflect the tumor pathological regression status \[[@pone.0234310.ref025]\], especially its limitation in distinguishing residual tumor from surrounding fibrosis \[[@pone.0234310.ref026]--[@pone.0234310.ref028]\], we evaluated the rectal cancer regression grade (RCRG) of the enrolled patients by referring to the quantification standard of histologic regression of rectal cancer after irradiation of Wheeler JM et al. \[[@pone.0234310.ref029]\]. Within this scoring criterion, the regression of rectal tumors was classified into three levels: RCRG 1: Sterilization or only microscopic foci of adenocarcinoma remaining, with marked fibrosis; RCRG 2: Marked fibrosis but macroscopic disease present; RCRG 3: Little or no fibrosis, with abundant macroscopic disease. In our study, we defined RCRG 3 as no/low response.

Statistical analysis {#sec008}
--------------------

Statistical analysis was performed using SPSS software 17.0 (SPSS, Inc., Chicago, IL, USA) and MedCalc Version 16.2. The relationships between the factors and the no/low response status are analyzed by forward stepwise Logistic regression model. The Hosmer-Lemeshow test was used to evaluate the goodness of fit of logistic regression model. A nomogram was formulated based on the results of logistic regression analysis and by using the Empower Stats software of R, version 3.0*(*[*http*:*//www*.*empowerstats*.*com*](http://www.empowerstats.com/)*)*. Receive operating characteristic (ROC) curve analysis was used to evaluate the prediction performance of the logistic regression model and the independent predictors. In our study, *P*\<0.05 was considered statistically significant.

Results {#sec009}
=======

Treatment characteristics and tumor response {#sec010}
--------------------------------------------

In this study, all enrolled patients completed preoperative CCRT according to the pre-established neoadjuvant treatment regimen. MRI images taken one week before resection showed that the down-staging rates of tumors and lymph nodes were 53.16% (42 cases) and 55.70% (44 cases), respectively, and the CRM status of all patients were negative. According to TME standards, surgical resection was performed 8--10 weeks after CCRT. Out of all enrolled patients, 17 underwent abdominoperineal resection, 62 underwent low anterior resection, none of whom underwent Hartmann surgery. Of the 62 patients who underwent low anterior resection, 12 underwent temporary protective loop ileostomy. The proximal and distal margins of all specimens were negative. The RCRG status of enrolled patients has been reported in our previous study \[[@pone.0234310.ref030]\] as follows: 20 (25.32%) cases for RCRG 1, 35(44.30%) for RCRG 2, 24 (30.38%) for RCRG 3, resulting in 24 patients showing no/low response to preoperative CCRT. There were 5 cases with positive CRM, all of which were found in RCRG 3 group. From a total of 18 cases with Lymph-vascular space invasion, 3 were found in RCRG 2 group and 15 found in RCRG 3 group. The relationship between the general characteristics of patients and the response to preoperative CCRT is shown in [Table 1](#pone.0234310.t001){ref-type="table"}.

10.1371/journal.pone.0234310.t001

###### Baseline demographics of all patients (N = 79).

![](pone.0234310.t001){#pone.0234310.t001g}

  Characteristic            Classification and delamination   Number       No/low response to preoperative CCRT(n = 24)   Obvious response preoperative CCRT(n = 55)
  ------------------------- --------------------------------- ------------ ---------------------------------------------- --------------------------------------------
  Age(years)                ≤40                               5            2(8.33%)                                       3(5.45%)
  41--50                    14                                2(8.33%)     12(21.82%)                                     
  51--60                    33                                11(45.83%)   22(40.00%)                                     
  61--70                    18                                5(20.83%)    13(23.64%)                                     
  ≥71                       9                                 4(16.67%)    5(9.09%)                                       
  Gender                    Male                              46           14(58.33%)                                     32(58.18%)
  Female                    33                                10(41.67%)   23(41.82%)                                     
  Clinical T stage          2                                 11           3(12.50%)                                      8(14.55%)
  3                         54                                16(66.67%)   38(69.09%)                                     
  4                         14                                5(20.83%)    9(16.36%)                                      
  Clinical N stage          0                                 11           1(4.17%)                                       10(18.18%)
  1                         39                                8(33.33%)    31(56.36%)                                     
  2                         29                                15(62.50%)   14(25.45%)                                     
  CEA(ng/ml)                ≤5                                39           11(45.83%)                                     28(50.91%)
  \>5                       40                                13(54.17%)   27(49.09%)                                     
  Pathological pattern      Non-mucinous adenocarcinoma       69           21(87.50%)                                     48(87.27%)
  Mucinous adenocarcinoma   10                                3(12.50%)    7(12.73%)                                      

CEA, Carcinoembryonic antigen.

The expression of CD44v6 {#sec011}
------------------------

Of the 79 patients examined for CD44v6, 33 (41.77%) had"-" expression, 21 (26.58%) had"+" expression, 17 (21.52%) had"++" expression, 8 (10.13%) was "+++" expression. These results have been reported in our previous study \[[@pone.0234310.ref030]\].

Correlation between parameters {#sec012}
------------------------------

Under the premise of no/low response to preoperative CCRT being a dependent variable, we selected age, gender, clinical T stage, clinical N stage, pathological pattern, serum CEA levels, CD44v6 expression, TML, TMD, ATV, RTV, TSAI, TSAO, TSA, along with TC as possible predictors on the basis of previous results \[[@pone.0234310.ref030]\], we stratified each factor according to its characteristics ([Table 2](#pone.0234310.t002){ref-type="table"}), and provided its value in the database ([S1 Data](#pone.0234310.s001){ref-type="supplementary-material"}). Collinearity analysis for all variables were performed before logistic regression analysis, and the results show that the variance inflation factor (VIF)≥7, including RTV (8.124) and ATV (7.391), were thought to be highly correlated with at least one of the other factors in the regression model. Considering that both ATV and RTV are descriptions of tumor size, we incorporated one of the two variables in the collinear analysis respectively, and found that, with either ATV or RTV included, VIF of all variables in the analysis model were still less than 6 ([Table 3](#pone.0234310.t003){ref-type="table"}).

10.1371/journal.pone.0234310.t002

###### The layering of all variable in regression model.

![](pone.0234310.t002){#pone.0234310.t002g}

  Variables              Label   The explanation of layering                                                     
  ---------------------- ------- ----------------------------- ------------------------ ----------- ------------ -------
  Hierarchy                      1                             2                        3           4            5
  Age(years)             X1      ≤40                           41--50                   51--60      61--70       ≥71
  Gender                 X2      Male                          Female                                            
  Clinical T stage       X3      T2                            T3                       T4                       
  Clinical N stage       X4      N0                            N1                       N2                       
  pathological pattern   X5      Non-mucinous adenocarcinoma   Mucinous adenocarcinom                            
  CEA(ng/mL)             X6      ≤5                            \>5                                               
  CD44v6                 X7      "-"                           "+"                      "++"        "+++"        
  TML (cm)               X8      ≤5                            \>5&≤8                   \>8&≤11     \>11         
  TMD (cm)               X9      ≤3                            \>3&≤5                   \>5&≤7      \>7          
  ATV (cm^3^)            X10     ≤35                           \>35&≤70                 \>70&≤105   \>105&≤140   \>140
  RTV (cm^3^)            X11     ≤35                           \>35&≤70                 \>70&≤105   \>105&≤140   \>140
  TSAI (cm^2^)           X12     ≤2                            \>2&≤4                   \>4&≤6      \>6          
  TSAO (cm^2^)           X13     ≤10                           \>10&≤20                 \>20&≤30    \>30         
  TSA (cm^2^)            X14     ≤10                           \>10&≤20                 \>20&≤30    \>30         
  TC                     X15     ≤1.0                          \>1.0&≤1.5               \>1.5&≤2    \>2&≤2.5     \>2.5

CEA, Carcinoembryonic antigen; TML, tumor maximum longitudinal length; TMD, tumor maximum transverse diameter; ATV, approximate tumor volume; RTV, real tumor volume; TSAI, tumor surface area inner the intestine; TSAO, tumor surface area outside the intestine; TSA, total surface area of tumor; TC, tumor compactness.

10.1371/journal.pone.0234310.t003

###### The variance inflation factors (VIFs) all variables in regression model.

![](pone.0234310.t003){#pone.0234310.t003g}

  Variables              Collinearity analysis                                   
  ---------------------- ----------------------- ------- ------- ------- ------- -------
  Age                    0.784                   1.275   0.788   1.269   0.796   1.256
  Gender                 0.712                   1.405   0.823   1.216   0.731   1.368
  Clinical T stage       0.855                   1.169   0.857   1.166   0.857   1.166
  Clinical N stage       0.776                   1.289   0.776   1.289   0.780   1.283
  pathological pattern   0.887                   1.127   0.890   1.124   0.890   1.123
  CEA                    0.775                   1.290   0.796   1.257   0.804   1.244
  CD44v6                 0530                    1.887   0.553   1.807   0.549   1.821
  TML                    0.692                   1.446   0.697   1.435   0.694   1.441
  TMD                    0.687                   1.456   0.687   1.456   0.692   1.445
  ATV                    0.135                   7.391                   0.233   4.292
  RTV                    0.123                   8.124   0.212   4.718           
  TSAI                   0.827                   1.210   0.833   1.200   0.845   1.184
  TSAO                   0.777                   1.287   0.777   1.286   0.781   1.280
  TSA                    0.172                   5.810   0.181   5.518   0.221   4.528
  TC                     0.695                   1.438   0.726   1.378   0.699   1.430

CEA, Carcinoembryonic antigen; TML, tumor maximum longitudinal length; TMD, tumor maximum transverse diameter; ATV, approximate tumor volume; RTV, real tumor volume; TSAI, tumor surface area inner the intestine; TSAO, tumor surface area outside the intestine; TSA, total surface area of tumor; TC, tumor compactness.

Multivariate analyses for no/low response status {#sec013}
------------------------------------------------

According to the results of the previous step, we found strong collinearity between ATV and RTV. We then separated them into subsequent goodness of fit test and multivariate analysis models. The significance of the Hosmer-Leme show goodness of fit was 0.318(incl RTV) and 0.886 (incl ATV) respectively, indicating that the model has a good degree of fit (*P\>0*.*05*). Multivariate analysis showed that, with deleting ATV from the model, TC was a negative predictor for no/low response status (*P = 0*.*018*), RTV and the CD44v6 expression were both positive predictors (*P = 0*.*001*, *P = 0*.*008*) ([Table 4](#pone.0234310.t004){ref-type="table"}), Logistic regression model was $Z1 = sigmoid(X) = \frac{1}{1 + e^{- 4.419 + 1.003 \times X7 + 1.557 \times X11 - 1.004 \times X15}}$. As we excluded RTV from the model, the results showed that CD44v6 expression and TSA were positive predictive factors (*P = 0*.*006*, *P = 0*.*008*) ([Table 4](#pone.0234310.t004){ref-type="table"}), Logistic regression model was $Z2 = sigmoid(X) = \frac{1}{1 + e^{- 6.547 + 0.864 \times X7 + 2.081 \times X14}}$. In the above models, Z1 and Z2 represent the probability of patients with no/low response to preoperative CCRT, *sigmoid(X)* was the activation function of logistic regression. When the value of Z1/Z2 is greater than the corresponding optimal cutoff, the patient can be judged as insensitive to preoperative CCRT. In order to facilitate clinical application, we formulated nomogram (Figs [2](#pone.0234310.g002){ref-type="fig"} and [3](#pone.0234310.g003){ref-type="fig"}) based on logistic regression analysis results, through which clinicians could evaluate the probability of no/low response of patients.

![Nomogram was used to predict the risk of no / low response of CCRT in LARC patients without ATV.](pone.0234310.g002){#pone.0234310.g002}

![Nomogram was used to predict the risk of no / low response of CCRT in LARC patients without RTV.](pone.0234310.g003){#pone.0234310.g003}

10.1371/journal.pone.0234310.t004

###### Significantly predictors of no/low response to preoperative CCRT in LARC.

![](pone.0234310.t004){#pone.0234310.t004g}

  Significantly predictors   Multivariate analysis                                             
  -------------------------- ----------------------- -------- ------- ------- -------- ------- ---------------
  Without ATV in model                                                                         
  CD44v6                     X7                      1.003    0.378   2.727   7.044    0.008   1.300--5.721
  RTV                        X11                     1.557    0.478   4.744   10.589   0.001   1.857--12.119
  TC                         X15                     -1.044   0.440   0.352   5.630    0.018   0.149--0.834
  Constant                                           -4.419   1.464   0.012   9.115    0.003   
  Without RTV in model                                                                         
  CD44v6                     X7                      0.864    0.327   2.373   6.973    0.008   1.250--4.506
  TSA                        X14                     2.081    0.754   8.010   7.618    0.006   1.828--35.103
  Constant                                           -6.547   1.597   0.001   16.810   0.000   

ATV, approximate tumor volume; RTV, real tumor volume; TC, tumor compactness; TSA, total surface area of tumor.

Evaluation of predictive value {#sec014}
------------------------------

The results of predictive performance of above Logistic regression models and volumetric imaging parameters significantly associated with the no/low response to CCRT were obtained by ROC analysis (Figs [4](#pone.0234310.g004){ref-type="fig"} and [5](#pone.0234310.g005){ref-type="fig"}). The Area Under Curve (AUC) of Z1, Z2, RTV, TC, and TSA were 0.900 (95%CI 0.811--0.965), 0.858(95%CI 0.761--0.926), 0.771(95%CI 0.663--0.858), 0.754 (95%CI 0.644--0.844), and 0.859 (95%CI 0.762--0.927), respectively. Based on the optimal cutoff values of 0.787, 0.658, 65.00 cm^3^, 1.35, and 14.54cm^2^, the sensitivity of Z1, Z2, RTV, TC, and TSA were 95.80%, 79.17%, 62.50%, 95.83%, 62.5%, the specificity were 70.90%, 74.55%, 83.64%, 47.27%, and 96.36%, the positive predictive values were 58.96%, 57.58%, 62.51%, 44.23%, and 88.23%, the negative predictive values were 97.48%, 89.13%, 83.64%, 96.29%, and 85.48%, respectively. These results suggest that the two regression models are of high predictive value, TC\'s predictive advantage is mainly reflected in its sensitivity, while TSA\'s is mainly reflected in its specificity.

![ROC curve of logistic regression formulas using the no/low response status as test variable.\
Z1 is the Logistic regression formula obtained after the deletion of ATV in the independent variable, Z2 is the Logistic regression formula obtained after the deletion of RTV in the independent variables.](pone.0234310.g004){#pone.0234310.g004}

![ROC curve of RTV, TC and TSA using the no/low response status as test variable.\
RTV represents real tumor volume, TSA represents total surface area of tumor, TC represents tumor compactness.](pone.0234310.g005){#pone.0234310.g005}

Discussion {#sec015}
==========

As an important part of the comprehensive treatment for LARC, preoperative CCRT can provide better local control, toxicity profile, and sphincter preservation than postoperative CCRT \[[@pone.0234310.ref031], [@pone.0234310.ref032]\]. However, it usually increases the risk of pelvic edema or pelvic fibrosis, while increasing the difficulty of surgery. In addition, Bertucci et al. found that preoperative radiation was the single most significant and controllable risk factor predicting perineal wound failure \[[@pone.0234310.ref033]\]. Anastomotic leakage is a very serious complication after colorectal surgery, which was increased in patients having undergone preoperative CCRT \[[@pone.0234310.ref034], [@pone.0234310.ref035]\]. Therefore, in patients showing no/low response to neoadjuvant therapy, preoperative CCRT cannot only delay the timing of surgery and enhance the complexity and difficulty of surgery, but also increase the risk of the a forementioned postoperative complications.

Evidence suggests that Cancer stem cells (CSCs) are responsible for the growth and recurrence of tumors and their resistance to radiotherapy \[[@pone.0234310.ref036], [@pone.0234310.ref037]\]. The underlying mechanisms include that CSCs are usually in cells S/G0 phase \[[@pone.0234310.ref038]\], which have powerful functions of replication and DNA damage repair, while tumor cells during G2/M phases are the most sensitive to radiotherapy \[[@pone.0234310.ref039], [@pone.0234310.ref040]\]. Furthermore, radiation transforms the division strategy of CSCs from asymmetry to symmetry, which in turn leads to an increase in the proportion of tumor stem cells either in proportion or in absolute numbers \[[@pone.0234310.ref041], [@pone.0234310.ref042]\]. It was found that CD44v6 is an important CSCs marker, its expression level was positively related to the resistance of chemotherapy and radiotherapy resistance of nasopharyngeal carcinoma, prostate cancer and rectal cancer \[[@pone.0234310.ref015], [@pone.0234310.ref016]\]. In this study, we found that the expression of CD44v6 was significantly higher in patients with chemoradiotherapy resistance than that of patients with chemoradiotherapy sensitivity and could be used as an independent predictor in order to predict the resistance of preoperative CCRT, which was consistent with the results of Huh et al. in screening for predictors of tumor regression after preoperative CCRT for rectal cancer \[[@pone.0234310.ref018]\].

Because the rectum is a hollow organ, the entire intestines at the tumor location are usually included in the scope of gross tumor volume (GTV) when the radiotherapy target is delineated. This will undoubtedly make the tumor volumetric parameters obtained greater than the true size of the tumor. RTV is the most precise parameter of the tumors volume obtained by eliminating intestinal volume. In this study, we analyzed correlations between the no/low response status of CCRT and RTV, ATV, respectively, and found that ATV could not be used as an independent predictor to predict the patient\'s resistance to CCRT, while RTV could. In previous studies, Chen et al. \[[@pone.0234310.ref043]\] found that GTV(actually ATV) was negatively correlated with the prognosis of patients with esophageal cancer after definitive radiotherapy, and numerous studies \[[@pone.0234310.ref022], [@pone.0234310.ref044], [@pone.0234310.ref045]\] on preoperative CCRT for rectal cancer have shown that tumor volume was negatively correlated with the pCR status after preoperative CCRT. Although the endpoint of these studies were pCR, it also suggested to some extent that larger tumors may have more no/low response to CCRT; our results bear this out.

TC is a parameter originated from tumor-measurable volumetric imaging parameters and has been found to be closely related to tumor morphology and invasiveness \[[@pone.0234310.ref024], [@pone.0234310.ref046], [@pone.0234310.ref047]\]. According to [Fave](https://www.ncbi.nlm.nih.gov/pubmed/?term=Fave%20X%5BAuthor%5D&cauthor=true&cauthor_uid=28373718) et al., TC not only reflects the information of tumor volume and TNM, but also the prognosis of non-small cell lung cancer patients \[[@pone.0234310.ref048]\]. From the equation of TC, there seems to be an inverse relationship between TC and TSA. It is well known that the value of TSA determines the degree of tumor contact with the surrounding tissues and organs. Studies by Agner et al. revealed that the TC value of triple-negative breast cancer was significantly higher than that of HER2-positive breast cancer, suggesting that the edge of triple-negative breast cancer is smoother than HER2-positive breast cancer \[[@pone.0234310.ref024]\]. Therefore, we hypothesized that the correlation between TC and tumor invasiveness may be due to the size of TSA. From the ROC curve analysis results, we found that the predictive specificity of TSA was 95.83%, while the predictive sensitivity of TC was 95.24%. This indicates that when the TSA value is greater than 14.54cm^2^, 96.36% of patients with LARC, who have non-obvious resistance the preoperative CCRT, can be identified, and when the TC value is less than or equal to 1.35, 95.83% of patients with LARC, who show no/low response to preoperative CCRT, can be screened out.

In our study, two predictive models of no/low response status were obtained and their predictive values were analyzed by ROC. It was found that the AUC values of both models were greater than 0.85, which means that they had good predictive performance. Therefore, for initial LARC patients, we can put relevant parameters in place to predict the patient\'s CCRT resistance. When the Z value is greater than the corresponding cut-off value, it can be considered that the patient will show no/low response to preoperative CCRT. The application of these two models would be instructive for the selection of treatment strategies for LARC patients. In addition, we can also include the statistically significant predictor values, such as the expression levels of CD44v6, RTV, TC, and TSA, into the nomogram to assess the probability of no / low response to preoperative CCRT.

Limitations {#sec016}
===========

This study has some limitations. To begin with, only patients receiving long-course preoperative CCRT were included, and patients receiving short-course preoperative radiotherapy were not included, thus limiting the predictive application of the obtained regression model for these patients. What cannot be ignored, however, is the number of patients receiving long-course CCRT in both China and the United States, which is far more than those receiving short-course radiotherapy. Taking this into account, our results still have reasonable representativeness and will be followed-up to verify the results of this study in patients receiving short-course preoperative radiotherapy. Another limitation of this study was that the pathology of pelvic lymph nodes could not be accurately obtained before surgery, therefore, imaging information of suspicious positive lymph nodes found in MRIs were not included as imaging parameters in the study, which will undoubtedly lead to the limitations of our results. The third limitation of this study is that the results we obtained have not appeared in the previous reports, plus there are fewer patients in this study (79 cases), so a larger cohort study still needs to be carried out. In addition, the practicability of our results also needs to be further verified in clinical practice. The final limitation was that we did not include the detection index of immunotherapy in our candidate factors. At present, studies have found that there is a correlation between the status of immunoassay indicators and the response of LARC patients to CCRT. For example, Hasan et al. analyzed the relationship between the response of 5086 rectal cancer patients to preoperative CCRT and microsatellite stability (MSI) by using the data of National Cancer Database (NCDB), and found that MSI(+) was related to the low pCR rate after CCRT \[[@pone.0234310.ref049]\]. Since Hasan\'s study was published in 2018 and our experiment started in 2015, this study did not include immunoassay indexes such as PD-1, PDL-1, MSI, and tumor cumulative burden (TMB). Despite such limitations, this study offers a unique perspective for the choice of treatment options for LARC patients.

Conclusion {#sec017}
==========

The logistic regression model we obtained is a method for preoperative prediction of patients\' suitability for neoadjuvant chemoradiotherapy. The application of this method would reduce the risk probability of those patients, who are not sensitive to CCRT, from suffering the corresponding radiation complications as well as longer waiting periods for surgery and would also provide evidence for individualized treatment options for LARC patients. Independent predictors for resistance status include CD44v6 expression level and tumor imaging volumetric parameters such as real tumor volume (RTV), tumor surface area (TSA) and tumor compactness (TC). These factors are of great value in predicting no/low response status of LARC patients to preoperative CCRT.

Supporting information {#sec018}
======================

###### Data of influencing factors.

(XLSX)

###### 

Click here for additional data file.
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Dear Dr. Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR:

1\. In the abstract, \"15 factors\" is better to be written as \"Fifteen factors\...\"

2\. In the letter to the editor, \"myco-authors\" should be \"my co-authors.\"

3\. Line 68, \"CD44v6,\" should not be Italic here. It is supposed to be a protein stained by an IHC method.  Please make sure all the CD44v6 in the manuscript has been correctly expressed. 

4\. Line 69-70, \"Breast cancer specimens were used to act as positive control samples, PBS (pH 7.4) was used as a negative control\"  They should be two different sentences. 

5\. The authors said that they used breast cancer samples for control. Was the breast cancer sample prospectively taken or a control slide? Otherwise, please make a clear statement of how the authors used breast cancer samples within the approval range of the IRB. 

5\. All the tables lack abbreviations independently. Please add them in the bottom of each tables.  

6\. No potential limitations were stated in the manuscript. Please kindly consider providing one paragraph for the limitations of the present study.

7\. In conclusion, the authors are recommended to be more humble. The findings here have not been independently validated. Please do not conclude that some patients should be \"saved\"  from the corresponding radiation complications. The conclusion is too aggressive and not scientific enough.​==============================

We would appreciate receiving your revised manuscript by Feb 14 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://doi.org/10.1093/jrr/rrz035>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

3\. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: <http://journals.plos.org/plosone/s/supporting-information>.

Additional Editor Comments (if provided):

1\. In the abstract, \"15 factors\" is better to be written as \"Fifteen factors\...\"

2\. In the letter to the editor, \"myco-authors\" should be \"my co-authors.\"

3\. Line 68, \"CD44v6,\" should not be Italic here. It is supposed to be a protein stained by an IHC method. Please make sure all the CD44v6 in the manuscript has been correctly expressed.

4\. Line 69-70, \"Breast cancer specimens were used to act as positive control samples, PBS (pH 7.4) was used as a negative control\" They should be two different sentences.

5\. The authors said that they used breast cancer samples for control. Was the breast cancer sample prospectively taken or a control slide? Otherwise, please make a clear statement of how the authors used breast cancer samples within the approval range of the IRB.

5\. All the tables lack abbreviations independently. Please add them in the bottom of each tables.

6\. No potential limitations were stated in the manuscript. Please kindly consider providing one paragraph for the limitations of the present study.

7\. In conclusion, the authors are recommended to be more humble. The findings here have not been independently validated. Please do not conclude that some patients should be \"saved\" from the corresponding radiation complications. The conclusion is too aggressive and not scientific enough.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The study included 79 patients with locally advanced rectal cancer with the inferior margin of tumor within 10 cm from the anal verge, clinical T2N+ or clinical T3-4 who were qualified for a long course preoperative CCRT. After a long course of preoperative CCRT all the patients were qualified for TME surgery. 15 parameters were evaluated to predict the low/no response to preoperative CCRT. I have a several doubts according to the qualification for CCRT, the type of surgery which was performed, the structure of the study, discussion and conclusions:

1)the patients qualified for the therapy had upper rectal cancer (10 cm from the anal verge)-from the data we do not know, which cancers were above peritoneal reflection (\>12 cm from the anal verge)\--\>these do not benefit from CRT and should be treated as colon cancer

2)in discussion there are mentioned disadvantages of CRT\--\>the problems with peritoneal wound healing (none of patients had peritoneal wound\--\>all had TME, no abdominoperineal resections), anastomotic leakage (no data about it, we do not know if the patients had protective artificial anus)

3)the factors which are the most important during surgery and in the local treatment of the rectal cancer are clear margins (circumferential\--\>positive in the group with low/no response to preoperative CCRT\--\>5 patients, negative in the group with obvious response to preoperative CCRT\--\>0 patients, the authors do not mention proximal and distal margins which are also important). We do not have data about MRI images after preoperative CCRT before surgery\--\>if the clear margins in advanced cT3-T4 are at risk (possible R1 or R2 resection), why to perform TME\--\>these patients should undergo multivisceral R0 resection if it is technically possible; we do not have information in which cT the margins were positive

4\) not all cT2N+/T3 tumors need preoperative CCRT if the quality of TME is high\--\>we do not have any information about the quality of surgery

5)even the low response to the preoperative CCRT may mean R0 surgery\--\>the shrinkage of the tumor should result in a clear CRM (\>1mm) so we should not discourage these patients from the preoperative CCRT; the pathologic regression in 24 patients meant no/low response, but only in 5 patients the CRM was positive

6)emotional, general expressions like \"in the real world\" (line 34) \"a catastrophe for the patients\" (line 174) should be omitted

7)endorectal ultrasound is not used for diagnosis of distant metastases (line 53)

7)grammatical and structural mistakes (line 40, 47, 48, 52, 164, 165, 179, 188, 203)

Reviewer \#2: This study by Wang et al. tries to identify independent prognostic factors of poor response of CRT in rectal cancer.

Here are my main points which could help to improve the manuscript.

1\. Table 1 should be replaced in results

2\. English by place could be improved by a native speaker

3\. The authors should better explain in Introduction what is CD44v6 and why it could be relevant in rectal cancer irradiation.

4\. It remains unclear whether poor response was defined according to pathological examination or with preoperative MRI.

5\. The authors report important results which could help decision making in the future. However, I suggest that an external cohort could validate these results.

6\. Again, to improve the manuscript, a prognostic nomogram including all relevant parameters should be proposed and would greatly improve the quality of the manuscript.

7\. Possible bias should be discussed.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear professor:

Thank you very much for your suggestion and guidance on our manuscript. After consulting the relevant literatures, we have revised our paper according to your suggestions and questions. Our answer as follows:

Response to Editor:

Our answer to question one ( In the abstract, \"15 factors\" is better to be written as \"Fifteen factors\...\") is as follows:

Thank you very much for your advice. In the abstract section, we have modified this error.

Our answer to question two (In the letter to the editor, \"myco-authors\" should be \"my co-authors.\") is as follows:

Thank you very much for your reminding. In the letter to the editor, we have modified this error.

Our answer to question three (Line 68, \"CD44v6,\" should not be Italic here. It is supposed to be a protein stained by an IHC method. Please make sure all the CD44v6 in the manuscript has been correctly expressed. ) is as follows:

Thank you very much for your reminding. We carefully checked the entire manuscript and made comprehensive corrections to the writing errors of CD44v6. Thanks again for your advice.

Our answer to question four (Line 69-70, \"Breast cancer specimens were used to act as positive control samples, PBS (pH 7.4) was used as a negative control\" They should be two different sentences. ) is as follows:

Thank you very much for your advice. We have modified this error accordingly in our revised version.

Our answer to question five (The authors said that they used breast cancer samples for control. Was the breast cancer sample prospectively taken or a control slide? Otherwise, please make a clear statement of how the authors used breast cancer samples within the approval range of the IRB. ) is as follows:

Thank you very much for your advice. Due to our negligence, the reason for using breast cancer samples as a positive control is not described in the manuscript. In this revised manuscript, we have shown the corresponding basis. Thank you again for your reminding.

Our answer to question six (All the tables lack abbreviations independently. Please add them in the bottom of each tables.) is as follows:

Thank you very much for your reminding. We have added abbreviations in the bottom of each table in revised version.

Our answer to question seven (No potential limitations were stated in the manuscript. Please kindly consider providing one paragraph for the limitations of the present study.) is as follows:

Thank you very much for your reminding. With your suggestion, we carefully read relevant literatures and conducted in-depth thinking and discussion. We found that our study does have some limitations, so we elaborated them one by one in the discussion section of the revised version.

Our answer to question eight (In conclusion, the authors are recommended to be more humble. The findings here have not been independently validated. Please do not conclude that some patients should be \"saved\" from the corresponding radiation complications. The conclusion is too aggressive and not scientific enough.) is as follows:

Thank you very much for your advice. Your criticism is correct and we have accepted it sincerely. In the conclusion section, we have deleted and modified those inappropriate statements.

Response to Reviewer\#1:

Our answer to question one (The patients qualified for the therapy had upper rectal cancer (10 cm from the anal verge)-from the data we do not know, which cancers were above peritoneal reflection (\>12 cm from the anal verge)\--\>these do not benefit from CRT and should be treated as colon cancer) is as follows:

Thank you very much for your reminding. With your suggestion, we carefully read relevant literatures. The relevant contents we have read are reported as follows: The rectum is defined as the distal 16 cm of the large intestine leading to the anal canal, and a cancer between 12 and 16 cm from the anal verge is classified as a rectal cancer of the upper third\[1,2\]. Previous studies have shown that neoadjuvant chemoradiotherapy have no significant effect on the upper rectal cancer \[3, 4\]. At present, most scholars believe that preoperative CCRT is necessary for tumor under the anterior peritoneal reflection. Memon \'s study showed that the mean distance from the anal verge to the anterior peritoneal reflection was 11.9 cm (men) and 10 cm (women) \[5\]. Studies by Peeters found that radiotherapy has a significant effect on reducing the risk of local recurrence in patients with lesions between 5 and 10 cm from the anal verge \[4\]. In China, most scholars defined between 10 and 15 cm from the anal verge as the upper rectum, 5-10 cm from the anal verge as the middle rectum, and 5 cm above the anal verge as the lower rectum \[6\]. Therefore, in this study, we took the distance of less than 10cm between the inferior margin of the tumor and the anal verge less than 10cm as one of the inclusion criteria.
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2\. Wittekind C, Greene FL, Henson C, eds. UICC. TNM Classification of Malignant Tumors, 6th ed. New York, NY: John Wiley & Sons; 2002.
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Our answer to question two (in discussion there are mentioned disadvantages of CRT\--\>the problems with peritoneal wound healing (none of patients had peritoneal wound\--\>all had TME, no abdominoperineal resections), anastomotic leakage (no data about it, we do not know if the patients had protective artificial anus)) is as follows:

Thank you for your advice. We have supplemented this part in the \"Operation and Pathologic regression status after CCRT\" section of the revised version, as described next: "Out of all enrolled patients, 17 underwent Miles surgery, 62 underwent Dixon surgery, none of whom underwent Hartmann surgery. Of the 62 patients who underwent Dixon surgery, 12 underwent a prophylactic terminal ileostomy". Thank you again for your reminding.

Our answer to question three (the factors which are the most important during surgery and in the local treatment of the rectal cancer are clear margins (circumferential\--\>positive in the group with low/no response to preoperative CCRT\--\>5 patients, negative in the group with obvious response to preoperative CCRT\--\>0 patients, the authors do not mention proximal and distal margins which are also important). We do not have data about MRI images after preoperative CCRT before surgery\--\>if the clear margins in advanced cT3-T4 are at risk (possible R1 or R2 resection), why to perform TME\--\>these patients should undergo multivisceral R0 resection if it is technically possible; we do not have information in which cT the margins were positive) is as follows:

Thank you for your reminding. Due to negligence, we did not show the situation of the proximal and distal margins in the manuscript, which caused you a lot of trouble in review, and we apologize deeply. We have supplemented this result in the \"Operation and Pathologic regression status after CCRT\" section of the revised version, as described next: "The proximal and distal margins of all specimens were negative."

In addition, the MRI images (after preoperative CCRT before surgery) showed that the status of CRM of all enrolled patients was negative, while the postoperative pathology showed that the CRM of 5 patients were positive, indicating that there was an error in the preoperative MRI evaluation of CRM. Therefore, we did not show them in the original manuscript. After receiving your suggestion, we realized the importance of presenting the CRM status of MRIs, so we supplemented these information in \"Table 1: baseline demographics of all patients\" in the revised version. Thank you again for your reminding.

Our answer to question four (not all cT2N+/T3 tumors need preoperative CCRT if the quality of TME is high\--\>we do not have any information about the quality of surgery) is as follows:

Thank you for your advice. At present, preoperative CCRT combined with TME as the standard treatment for LARC patients has been written into many guidelines. In clinical practice, as you said, we did experience many patients with cT2N+/T3 who did not undergo preoperative CCRT but preferred TME surgery and achieved good results. However, 79 patients enrolled in this study were given the treatment plan at the experimental design stage, so they all adopted preoperative CCRT. With your suggestion, we supplemented the information about the quality of surgery in the\" Preoperative CCRT and surgery\" section of the revised manuscript as follows: "Total mesorectal excision (TME) surgery was performed by two surgeons with more than 15 years of experience at 8 to 10 weeks after CCRT, each of whom completed at least 100 rectal cancer surgeries per- year". Thank you again for your reminding.

Our answer to question five (even the low response to the preoperative CCRT may mean R0 surgery\--\>the shrinkage of the tumor should result in a clear CRM (\>1mm) so we should not discourage these patients from the preoperative CCRT; the pathologic regression in 24 patients meant no/low response, but only in 5 patients the CRM was positive) is as follows:

What you said is very reasonable. It is true that many patients did not reach the stage of pathological decline after receiving the neoadjuvant therapy, but the tumor volume was reduced, thus R0 resection was performed. What cannot be ignored, however, is that there are still some patients not only did not achieve pathological decline and tumor volume shrinkage after CCRT, but also developed further aggravation. We all know that perioperative adjuvant treatment includes preoperative treatment and postoperative treatment. If we can identify these patients who are not sensitive to preoperative CCRT before treatment (the purpose of this study), give them active surgical treatment and then carry out postoperative radiotherapy and systemic treatment, these patients may receive greater benefits.

Our answer to question six (emotional, general expressions like \"in the real world\" (line 34) \"a catastrophe for the patients\" (line 174) should be omitted) is as follows:

Thank you for your advice. We have deleted these contents in the revised manuscript.

Our answer to question seven (endorectal ultrasound is not used for diagnosis of distant metastases (line 53)) is as follows:

Thank you for your advice. We have deleted this content in the revised manuscript. Thank you again for your reminding.

Our answer to question eight (grammatical and structural mistakes (line 40, 47, 48, 52, 164, 165, 179, 188, 203)) is as follows:

Thank you for your advice. With your suggestion, we invited native English speakers to proofread the language of this manuscript.

Response to Reviewer\#2:

Our answer to question one (Table 1 should be replaced in results) is as follows:

According to your opinion, we rearranged the pathological results related to tumor regression in Table 1 into the results section of this manuscript.

Our answer to question two (English by place could be improved by a native speaker) is as follows:

Thank you for your advice. With your suggestion, we invited native English speakers to proofread the language of this manuscript.

Our answer to question three (The authors should better explain in Introduction what is CD44v6 and why it could be relevant in rectal cancer irradiation) is as follows:

Your opinion is reasonable. We have explained CD44v6 in the introduction section of the revised version. Thank you for your advice.

Our answer to question four (It remains unclear whether poor response was defined according to pathological examination or with preoperative MRI) is as follows:

Thank you for your reminding. We know that as you said, there are no unified standards for evaluating the efficacy of preoperative CCRT in patients with rectal cancer. Common methods include preoperative imaging evaluation (especially MRI) and postoperative pathology evaluation. However, these methods focus more on patients who are sensitive to neoadjuvant therapy because some of these patients may choose the \"watch and wait\" strategy. But even among those patients who were evaluated as cCR, some relapsed during the \"watch and wait\" strategy. In clinical practice, we often meet some patients who underwent MRI examination 8-10 weeks after receiving the preoperative CCRT and found that the imaging T stage did not change significantly from the original MRI results, but the postoperative pathology displayed tumor regression. Therefore, the tumor regression status indicated by MRI after CCRT and before surgery can not be used as the gold standard for evaluating the response of lesions to CCRT, but can only be used as an important reference.

Our answer to question five (The authors report important results which could help decision making in the future. However, I suggest that an external cohort could validate these results) is as follows:

Thank you for your reminding. Your suggestion is very important for our follow-up work. In the follow-up work, we will not only verify it in patients with long-course preoperative CCRT, but also in patients with short-course preoperative radiotherapy. These contents are described in the Limitations section of the revised version.

Our answer to question six (Again, to improve the manuscript, a prognostic nomogram including all relevant parameters should be proposed and would greatly improve the quality of the manuscript.) is as follows:

Thank you very much for your reminding. We have drawn the nomogram chart in the revised draft and elaborated it in the results and discussion section. Thanks again for your advice.

Our answer to question seven (Possible bias should be discussed) is as follows:

According to your opinion, I discussed the bias and limitations of our study in the Discussion section of the revised version.

Thank you and best regards.

Yours sincerely,

The author of PONE-D-19-31144

February 20, 2020
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Dear Dr Wang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: The manuscript has been improved. However, some crucial issues require revision. 

1\. Please respond to the reviewers\' comments in a point-by-point manner.  

2\. The authors wrote that \"the tumor stem cell marker CD44v6, which has been reported to be related to the resistance of neoadjuvant chemoradiation in rectal cancer \[5\].\" The writing was not clear for readers who are not working in this field. Please add one paragraph (or several sentences) to briefly introduce the role of CD44v6 in colorectal cancer and describe the reason(s) why the study chose this factor. 

==============================

We would appreciate receiving your revised manuscript by May 14 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The manuscript has been improved. However, some crucial issues require revision.

1\. Please respond to the reviewers\' comments in a point-by-point manner.

2\. The authors wrote that \"the tumor stem cell marker CD44v6, which has been reported to be related to the resistance of neoadjuvant chemoradiation in rectal cancer \[5\].\" The writing was not clear for readers who are not working in this field. Please add one paragraph (or several sentences) to briefly introduce the role of CD44v6 in colorectal cancer and describe the reason(s) why the study chose this factor.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: N/A

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I have several doubts and proposals for improvement of the article:

1)line 36\--\>\"preoperative CCRT will result\"\--\>I would change into\" preoperative CCRT may result\"

2)line 51\--\> should be August 2017

3)line 117-120. I have doubts about terminology of surgical procedures and surgical technique: Miles technique=abdominoperineal resection is always associated with end-colostomy formation,

Dixon surgery-a type of blunt dissection\"Until the late 1970s, anterior resection with blunt dissection of the mid and distal rectum (as described by Dixon) continued to have a disease-free five-year survival rate for all stages treated with curative intent not exceeding 50% with a local recurrence rate of up to 20%. This was mainly related to the breaches often created on the mesorectal fascia and the mesorectum itself during the blunt rectal dissection\". Nowadays a standard procedure is TME introduced be RJ Heald-\"A surgical plane is a "potential space between contiguous organs which can be reproducibly created by dissection" . In rectal surgery the plane develops between the mesorectum and the surrounding somatic structures . Dissection along this plane should be sharp, under direct vision and gentle continuous traction\".

Question about ileostomy\--\>usually the temporary protective loop ileostomy is performed, not a terminal ileostomy.

Article about the terminology and technique-

Minim Invasive Ther Allied Technol 25 (5), 226-33 Oct 2016

Techniques and Technology Evolution of Rectal Cancer Surgery: A History of More Than a Hundred Years

Marco Maria Lirici , Cristiano G S Hüscher

Reviewer \#2: 1. Table 1 has not been moved to the Results Scetion

2\. The role of CD44v6 is still little described in Introduction

3\. Response to my fourth question remains unclear. Please provide a clear respsonse and define in Methods whether poor response was defined according to preoperative MRI or to pathological examination.

4\. Response to my fifth question is again approximate. I suggest to add to Limitations that an external cohort could be useful to validate this results and would strengthen your results.

5\. Figure 2 is unreadable.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Maciej Sebastian

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

21 Apr 2020

Dear professor:

Thank you very much for your suggestion and guidance on our manuscript. After consulting the relevant literatures, we have revised our paper according to your suggestions and questions. Our answer as follows:

Response to Editor:

Our answer to question one (Please respond to the reviewers\' comments in a point-by-point manner) is as follows:

Thank you very much for your advice. In this reply, we give a point-to-point response to each comment of the reviewers.

Our answer to question two (The authors wrote that \"the tumor stem cell marker CD44v6, which has been reported to be related to the resistance of neoadjuvant chemoradiation in rectal cancer \[5\].\" The writing was not clear for readers who are not working in this field. Please add one paragraph (or several sentences) to briefly introduce the role of CD44v6 in colorectal cancer and describe the reason(s) why the study chose this factor.) is as follows:

Thank you very much for your reminding. In the introduction of this revised manuscript, we added a paragraph to describe the relationship between the expression of CD44v6 and the patient\'s response to radiation.

Response to Reviewer\#1:

Our answer to question one (line 36\--\>\"preoperative CCRT will result\"\--\>I would change into\" preoperative CCRT may result\") is as follows:

Thank you very much for your reminding. We corrected this error in the revised manuscript.

Our answer to question two (line 51\--\> should be August 2017) is as follows:

Thank you for your advice. We corrected this error in the revised manuscript.

Our answer to question three (line 117-120. I have doubts about terminology of surgical procedures and surgical technique: Miles technique=abdominoperineal resection is always associated with end-colostomy formation,Dixon surgery-a type of blunt dissection\"Until the late 1970s, anterior resection with blunt dissection of the mid and distal rectum (as described by Dixon) continued to have a disease-free five-year survival rate for all stages treated with curative intent not exceeding 50% with a local recurrence rate of up to 20%. This was mainly related to the breaches often created on the mesorectal fascia and the mesorectum itself during the blunt rectal dissection\". Nowadays a standard procedure is TME introduced be RJ Heald-\"A surgical plane is a "potential space between contiguous organs which can be reproducibly created by dissection" . In rectal surgery the plane develops between the mesorectum and the surrounding somatic structures . Dissection along this plane should be sharp, under direct vision and gentle continuous traction\".

Question about ileostomy\--\>usually the temporary protective loop ileostomy is performed, not a terminal ileostomy.

Article about the terminology and technique-Minim Invasive Ther Allied Technol 25 (5), 226-33 Oct 2016 Techniques and Technology Evolution of Rectal Cancer Surgery: A History of More Than a Hundred Years Marco Maria Lirici , Cristiano G S Hüscher) is as follows:

Thank you very much for your reminding. After carefully reading the article you recommended, we modified the non-standard description in our article. At present, TME operation has been widely used in mainland China, but most clinicians still use the original operation name in their daily work, for example, the APR operation is called Miles, and the low anterior resection is called Dixon. This habitual title is not rigorous. Your reminder is very meaningful to us. We will correct it in our future clinical work and scientific research writing. In addition, in our revised version, terminal ileostomy was changed to temporary protective loop ileostomy. Thanks again!

Response to Reviewer\#2:

Our answer to question one (Table 1 has not been moved to the Results Scetion) is as follows:

According to your opinion, we moved Table 1 to the result section and briefly described it in the revised manuscript.

Our answer to question two (The role of CD44v6 is still little described in Introduction) is as follows:

Thank you for your advice. In the introduction of this revised manuscript, we added a paragraph to describe the relationship between the expression of CD44v6 and the patient\'s response to radiation.

Our answer to question three (Response to my fourth question remains unclear. Please provide a clear respsonse and define in Methods whether poor response was defined according to preoperative MRI or to pathological examination.) is as follows:

Your opinion is reasonable. We added this part in the materials and methods of this revised manuscript, and described the relevant results in our results section.

Our answer to question four (Response to my fifth question is again approximate. I suggest to add to Limitations that an external cohort could be useful to validate this results and would strengthen your results.) is as follows:

Thank you for your reminding. We added this part to the Limitations of this revised manuscript. The details are as follows: The third limitation of this study is that the results we obtained have not appeared in the previous reports, plus there are fewer patients in this study (79 cases), so a larger cohort study still needs to be carried out. In addition, the practicability of our results also needs to be further verified in clinical practice.

Our answer to question five (Figure 2 is unreadable.) is as follows:

Thank you for your reminding. In this picture upload, we divided figure 2 into Fig.2 and Fig.3.

Thank you and best regards.

Yours sincerely,

The author of PONE-D-19-31144

April 21, 2020

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Hsieh

Jason Chia-Hsun

Academic Editor

© 2020 Jason Chia-Hsun Hsieh

2020

Jason Chia-Hsun Hsieh

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

26 May 2020

Analysis of influencing factors of no/low response to preoperative concurrent chemoradiotherapy in locally advanced rectal cancer

PONE-D-19-31144R2

Dear Dr. Wang,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Jason Chia-Hsun Hsieh, M.D. Ph.D

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

All the issues were addressed adequately.

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: After all the changes which were made by the authors article is now well readable, technically sound and correct and leads to the correct conclusions.

I would only correct two vocabulary mistakes:

line 34-should be \"clinical practice\"

line 281 and 283-should be \"LARC\"

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Maciej Sebastian

Reviewer \#2: No

10.1371/journal.pone.0234310.r006
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© 2020 Jason Chia-Hsun Hsieh
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Jason Chia-Hsun Hsieh

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

29 May 2020

PONE-D-19-31144R2

Analysis of influencing factors of no/low response to preoperative concurrent chemoradiotherapy in locally advanced rectal cancer

Dear Dr. Wang:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jason Chia-Hsun Hsieh

Academic Editor

PLOS ONE
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